More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Share on Pinterest A new study found that GLP1-RA medications may help lower the risk of a cardiovascular event in people with type 2 diabetes. Getty Images Researchers say GLP-1 drugs prescribed for ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the ...

New research reveals these medications impact everything from heart health to restaurant menus.

Previously hailed – or derided – as weight-loss aids for the rich and famous, drugs such as Mounjaro, Wegovy and Ozempic took on a far more expansive role in 2025. No longer just considered treatments ...

This is read by an automated voice. Please report any issues or inconsistencies here. Ozempic, Zepbound, and Wegovy are now household names. And as these GLP-1 medications have exploded in popularity, ...

The popularity of GLP-1 weight-loss medications continues to soar—and their uptake is helping to push down obesity rates on a national scale—but a safe, evidence-based way off the drugs isn’t yet in ...

GLP-1 receptor agonists are being linked to a long list of benefits besides weight loss and diabetes, as evidence suggests they can lower the risk of conditions ranging from cancer and addiction to ...